My Clinical Perspective on a Complex Problem

Throughout my years of specialized gastroenterology practice at Hospital Universitario La Paz and my private clinic, I have treated hundreds of patients with diarrhea-predominant irritable bowel syndrome (IBS-D) accompanied by persistent gas. This condition, which significantly affects quality of life, requires a comprehensive approach based on the best available scientific evidence.

As a specialist recognized with the TopDoctors 2024 Award and member of international scientific societies (SEPD, SEED, ESGE), my therapeutic approach is founded on critical review of the most recent medical literature, combined with my direct clinical experience of over 15 years treating functional digestive disorders.

Mucoprotectants: The Promising Role of Xyloglucan

My Experience with Gelsectan (xyloglucan + tannins + pea protein)

In my clinical practice, I have observed promising results with the use of mucoprotectants containing xyloglucan, especially in patients with IBS-D presenting symptoms of persistent diarrhea and significant abdominal distension.

The current scientific evidence, although limited, is encouraging. A randomized crossover clinical trial demonstrated that the combination of xyloglucan, pea protein, and tannins achieved significant stool normalization in 87% of patients versus 0% with placebo (p=0.0019) during 28 days of treatment.

Current Limitations: It's important to note that the most recent American Gastroenterological Association clinical guidelines do not include xyloglucan among standard pharmacological recommendations for IBS-D, due to the need for more high-quality studies and robust comparative evidence.

My Recommendation: I consider xyloglucan a valid option in selected patients, especially those who have not responded adequately to dietary measures and conventional first-line treatments.

Amitriptyline: Evidence-Backed Second-Line Treatment

Robust Scientific Evidence

Amitriptyline, a tricyclic antidepressant, represents one of the most solid therapeutic options in my arsenal for managing refractory IBS-D. Major American scientific societies support its use:

• American Gastroenterological Association (AGA): Recommends tricyclic antidepressants, including amitriptyline, in IBS-D patients who do not respond to first-line therapies
• American College of Gastroenterology (ACG): Supports its use for symptomatic relief in IBS, highlighting its effect on visceral pain

My Dosing Protocol

Based on clinical guidelines and my experience:

• Initial dose: 10 mg at bedtime
• Titration: Gradual increase according to tolerance and response
• Maximum dose: 30 mg/day in primary care practice
• Monitoring: Assessment of adverse effects (dry mouth, sedation)

Safety Profile: Studies show that the discontinuation rate due to side effects is not significantly higher than with placebo, confirming its acceptable safety profile under appropriate medical supervision.

Physical Exercise: Modest but Consistent Benefit

Evidence for Exercise in Functional Digestive Disorders

Although the American College of Gastroenterology classifies exercise evidence as low quality with weak recommendation, my clinical experience and available studies suggest real benefit in selected patients.

My Recommended Exercise Protocol

Based on available evidence and my clinical experience:

• Type: Moderate-intensity aerobic exercise (walking, cycling, swimming)
• Frequency: 30 minutes, 4-5 days per week
• Intensity: Moderate (avoid intense exercise that may exacerbate symptoms)
• Complementary activities: Yoga and relaxation techniques

Important: Personalization is key. Some patients may experience initial worsening of symptoms with intense exercise, so I always recommend starting gradually and adjusting according to individual tolerance.

Simethicone: Limited Evidence in My Experience

The Reality About Simethicone

Despite being FDA-approved for symptomatic relief of gastrointestinal gas, my clinical experience of over 15 years coincides with what the scientific literature shows: simethicone's efficacy is limited and primarily subjective.

My Clinical Experience: In daily practice, I observe that patients using simethicone rarely experience significant and sustained improvement of their gas and bloating symptoms. Benefits, when they occur, are usually temporary and do not address the underlying cause of the problem.

My Recommendation: I do not usually prescribe simethicone as primary treatment for gas in IBS-D. I prefer to focus on treatments with greater scientific support and demonstrated clinical efficacy.

Probiotics: Limited Role According to Current Evidence

The Reality of Probiotics in IBS-D

Although there is some interest in probiotics for IBS-D, the American College of Gastroenterology is clear: the recommendation is weak and evidence quality is low due to heterogeneity between studies and lack of robust data on specific strains.

My Clinical Position on Probiotics

Although recent meta-analyses suggest that some combinations of Bifidobacterium and Lactobacillus may reduce symptom persistence (RR ≈ 0.79), I consider that:

• The benefit is minimal compared to other available interventions
• There is no standard formulation backed by solid evidence
• Costs can be significant for uncertain benefit
• They do not replace therapies with greater scientific evidence

My Recommendation: I do not consider probiotics as first-line treatment in IBS-D. When I use them, it's as complementary therapy in specific cases and always after implementing measures with greater scientific support.

My Personalized Therapeutic Algorithm

Evidence-Based Stepped Approach

Conclusions and Future Perspectives

Managing diarrhea-predominant irritable bowel syndrome with persistent gas requires a multidisciplinary approach based on the best available scientific evidence. My experience as a specialist has taught me that there is no single solution for all patients.

Mucoprotectants like xyloglucan represent a promising option with emerging evidence, while amitriptyline is consolidated as second-line treatment supported by major international scientific societies.

It is essential to maintain realistic expectations about treatments like simethicone and probiotics, whose scientific evidence is limited or contradictory, and focus our efforts on interventions with greater scientific support and demonstrated clinical efficacy.